Abingworth Bioventures 8 closes on $465m
Abingworth has held a final close for its new life sciences fund, Abingworth Bioventures 8 (ABV 8), on its $465m hard-cap, exceeding its $375m target.
More on Funds
Quadrivio plans first close for EUR 500m Lifestyle Fund II by mid-2023
Italy-based GP will expand predecessor Made in Italy vehicle’s focus beyond Italy to target European SMEs
Nation 1 launches new early-stage, EUR 35m-EUR 40m fund
Czech investor targets first close in 1Q24, seeking to attract institutional investors and at least one bank
Keyhaven eyes Q4 2023 fund launch amidst lower mid-market GP-leds boom
Secondaries firm looks ahead to fourth fund; sweet spot of EUR 50m-100m for deals but can go up to EUR 500m
GP Profile: Inspirit anticipates carve-outs uptick with fundraising on the horizon by year-end
Complex carve-outs specialist could raise around GBP 75m for its second fund with debut vehicle around 70% deployed
Latest News
Quadrivio plans first close for EUR 500m Lifestyle Fund II by mid-2023
Italy-based GP will expand predecessor Made in Italy vehicle’s focus beyond Italy to target European SMEs
AnaCap reaps 4.3x on MRH Trowe minority stake sale to TA Associates
German insurance broker will now be backed by both GPs; deal comes 2.5 years into AnaCap's investment period
Bregal poaches Carlyle exec for new chief investment officer role
Ryan Selwood’s appointment follows other recent senior hires, including a chief people officer and a chief technology officer
Cinven’s indicative EUR 10 per share Synlab bid seen as below fair value
Sponsor listed the laboratory testing service provider at EUR 18 per share in 2020